Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
Caroline SköldKim KultimaEva FreyhultAnders O LarssonTorsten GordhNils P HailerHans MallminPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)
Two subcutaneous denosumab injections 6 months apart increase RANKL and depress TNFRSF9 after THA. This provides a possible explanation for the rebound effect on bone turnover markers as well as bone mineral density (BMD) upon withdrawal of denosumab. None of the other measured markers of inflammation was influenced by denosumab treatment.
Keyphrases
- bone mineral density
- postmenopausal women
- body composition
- nuclear factor
- clinical trial
- total hip arthroplasty
- rheumatoid arthritis
- oxidative stress
- poor prognosis
- randomized controlled trial
- giant cell
- toll like receptor
- binding protein
- combination therapy
- phase ii
- placebo controlled
- ultrasound guided
- smoking cessation